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http://dx.doi.org/10.1016/j.ccell.2015.06.006SUMMARYAlthough clinically tested JAK inhibitors reduce splenomegaly and systemic symptoms,molecular responses
are not observed in most myeloproliferative neoplasm (MPN) patients. We previously demonstrated that
MPN cells become persistent to type I JAK inhibitors that bind the active conformation of JAK2. We investi-
gated whether CHZ868, a type II JAK inhibitor, would demonstrate activity in JAK inhibitor persistent
cells, murine MPN models, and MPN patient samples. JAK2 and MPL mutant cell lines were sensitive to
CHZ868, including type I JAK inhibitor persistent cells. CHZ868 showed significant activity in murine MPN
models and induced reductions in mutant allele burden not observed with type I JAK inhibitors. These
data demonstrate that type II JAK inhibition is a viable therapeutic approach for MPN patients.INTRODUCTION
Myeloproliferative neoplasms (MPNs) are myeloid malignancies
that present as clonal expansion of one ormoremyeloid lineages
(Dameshek, 1951). The most common MPNs are polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofi-
brosis (PMF). These MPNs are characterized by an increased
risk of thrombosis and bleeding, transformation to acute leuke-Significance
Although clinically tested JAK inhibitors provide clinical benefi
most MPN patients treated with them. We previously demons
inhibitors, which bind the active conformation of JAK2 and ena
We show that the type II inhibitor CHZ868, which binds JAK2 i
hibitor persistent cells. CHZ868 shows increased efficacy in
including significant reductions in allele burden not observed w
that type II JAK inhibitors can provide improved JAK2 target imia, and bone marrow fibrosis. Mutational studies identified so-
matic JAK2V617F mutations in 95% of PV and 50%–60% of
ET/PMF cases (Baxter et al., 2005; James et al., 2005; Kralovics
et al., 2005; Levine et al., 2005; Zhao et al., 2005). Subsequent
studies identified JAK2 exon 12 mutations in JAK2V617F-nega-
tive PV (Scott et al., 2007),MPL (thrombopoietin receptor) muta-
tions in JAK2V617F-negative ET/PMF cases (Beer et al., 2008;
Pardanani et al., 2006; Pikman et al., 2006; Vannucchi et al.,t to MPN patients, molecular responses are not observed in
trated that MPN cells can acquire persistence to type I JAK
ble activation of JAK2 in trans by other JAK family members.
n the inactive conformation, retains efficacy in type I JAK in-
murine models of polycythemia vera and myelofibrosis,
ith first-generation JAK inhibitors. These data demonstrate
nhibition, offering increased therapeutic efficacy.
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Figure 1. Type II JAK2 Inhibition by CHZ868 in Naive MPN Cells
(A) Proliferation with increasing concentrations of CYT387 (mM) relative to proliferation in the presence of DMSO as control is shown for naive SET2 cells and for
SET2 cells chronically cultured in the presence of CYT387 (CYTper SET2) (left). IC50 values for CYT387 are indicated in naive SET2 and in CYT
per SET2 (right). Data
of both panels are indicated as mean ± SEM.
(legend continued on next page)
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2008), and CALR mutations in JAK2/MPL WT ET/PMF cases
(Klampfl et al., 2013; Nangalia et al., 2013).
These discoveries, underscored by recent studies showing
that activated JAK-STAT signaling is a characteristic feature of
MPNs (Rampal et al., 2014), have led to the clinical development
of JAK kinase inhibitors in these diseases. In 2011, the JAK1/
JAK2 inhibitor ruxolitinib was approved for PMF and post-
PV/ET myelofibrosis (MF). Therapy with ruxolitinib and other
JAK kinase inhibitors ameliorates splenomegaly and constitu-
tional symptoms inMF patients (Harrison et al., 2012; Verstovsek
et al., 2012), and longer term follow-up suggests ruxolitinib ther-
apy is associated with improved survival compared with placebo
or best available therapy (Cervantes et al., 2013; Verstovsek
et al., 2013).
Despite these clinical benefits, chronic therapy with JAK inhib-
itors has not led to molecular or pathologic remissions in the
majority of MPN patients (Harrison et al., 2012; Verstovsek
et al., 2012) in contrast to ABL kinase inhibitors in chronic
myeloid leukemia. The observation that MPN patients do not
acquire second-site resistance mutations in JAK2 during JAK in-
hibitor therapy suggested that MPN cells are able to survive JAK
kinase inhibition in the absence of clonal evolution. We recently
demonstrated that MPN cells can acquire an adaptive form of
resistance, which we termed persistence, to JAK inhibitors
through reactivation of JAK-STAT signaling via heterodimeriza-
tion and transactivation of JAK2 by JAK1 and TYK2 (Koppikar
et al., 2012). shRNA and genetic studies demonstrate that
MPN cells remain highly dependent on JAK2 even after in vivo
treatment with JAK inhibitors, suggesting approaches that better
inhibit JAK2 kinase activity might offer increased therapeutic
efficacy (Bhagwat et al., 2014).
Current JAK2 inhibitors in clinical development are type I ki-
nase inhibitors, which stabilize the active kinase conformation.(B) The STAT5 gene expression signature as described by Schuringa et al. (2004)
naive SET2 cells.
(C) The apoptosis gene expression signature as described by Alcala´ et al. (2008)
naive SET2 cells.
(D) The IC50 values for CYT387, SAR302503, and BMS911543 in SET2 cells chron
SEM along with the respective IC50 values in naive SET2 cells.
(E) The proliferation of Ba/F3 cells stably expressing JAK2 V617F, JAK1 V658F, o
shown relative to proliferation in the presence of DMSO. Data are represented a
experiments performed in triplicate.
(F) Proliferation of JAK2V617F SET2 cells in increasing concentrations of inhibito
and ruxolitinib in SET2 cells are indicated in the inset. All data are represented a
(G) Proliferation of 32D cells expressingMPLW515L in increasing concentrations
CHZ868 and ruxolitinib in 32D MPLW515L cells are indicated in the inset. All dat
(H) The effect of CHZ868 on phosphorylation of JAK2, STAT3 and STAT5 in SET
(I) Induction of apoptosis by increasing concentrations of CHZ868 as compared w
the proportion of caspase-3-positive cells by representative flow cytometry histo
(J) The effect of increasing concentrations of CHZ868 on the phosphorylation of
JAK2 V617F as compared with EPOR JAK2 WT Ba/F3 cells.
(K) Densitometry of pSTAT5 and pSTAT3 western blot bands displayed in Figure
(L) Proliferation of EPOR JAK2 V617F Ba/F3 cells in the presence of increasing
compared with the proliferation of EPOR JAK2 WT Ba/F3 cells. Data are repre
experiments performed in triplicate.
(M) Proliferation of EPOR JAK2 V617F Ba/F3 cells in the presence of increasing
compared with the proliferation of EPOR JAK2 WT Ba/F3 cells. Data are repre
experiments performed in triplicate.
(N) The ratio of IC50 for CHZ868 to IC50 for ruxolitinib is compared for EPOR JAK2
*p < 0.05.
See also Figure S1.A recent study reported that BBT594, a type II kinase inhibitor
originally devised to inhibit the T315I BCR-ABL resistance allele,
was able to inhibit JAK2 activity in vitro. BBT594 binds JAK2 in
the inactive conformation (‘‘DFG-out’’ state), where the inhibitor
occupies the ATP binding site and an induced hydrophobic
pocket (Andraos et al., 2012). The inactive conformation was
stabilized consistent with decreased phosphorylation of the acti-
vation loop. However, BBT594 has limitations in potency and in
selectivity for JAK2 and does not have pharmacokinetic proper-
ties for in vivo use. Thus, there is a need to develop type II JAK2
inhibitors with improved potency, selectivity, and pharmacoki-
netics. Here, we investigate the activity of CHZ868, a type II
JAK2 inhibitor, in JAK inhibitor persistent cells, preclinical MPN
models, and patient samples as an additional approach to ther-
apeutic targeting of JAK2.
RESULTS
A Common Mechanism of Persistence to Type I
JAK Inhibitors
Upon prolonged exposure to ruxolitinib, MPN cells become
insensitive by acquiring a persistence phenotype with reacti-
vation of JAK-STAT signaling (Koppikar et al., 2012). We inves-
tigated whether a similar mechanism of drug persistence
would be observed with the type I JAK inhibitors CYT387,
BMS911543, and SAR302503. We cultured JAK2V617F SET2
cells and MPLW515L expressing 32D and TF-1 cells in the
presence of different JAK inhibitors for 8–10 weeks. Upon
chronic exposure to CYT387, BMS911543, and SAR302503,
JAK2V617F- and MPLW515L-mutant MPN cells acquired a
persistence phenotype with a 5- to 30-fold increase in IC50 to
each drug compared with naive cells (Figures 1A and S1A–
S1D). CYT387, BMS911543, and SAR302503 did not inhibitis tested for enrichment by GSEA in type I JAK inhibitor persistent cells versus
is tested for enrichment by GSEA in type I JAK inhibitor persistent cells versus
ically cultured in the presence of CYT387 (CYTper SET2) are shown as mean ±
r TYK2 V678F in the presence of increasing concentrations of CHZ868 (mM) is
s mean ± SEM. Indicated IC50 values represent the mean of two independent
r versus DMSO is shown for CHZ868 and for ruxolitinib. IC50 values of CHZ868
s mean ± SEM.
of inhibitor versus DMSO is shown for CHZ868 and for ruxolitinib. IC50 values of
a are represented as mean ± SEM.
2 cells is shown in comparison to ruxolitinib.
ith ruxolitinib is shown in JAK2V617F SET2 cells and in 32DMPLW515L cells as
grams (left) and by bar graphs indicating data as mean ± SEM (right).
JAK2, STAT3, and STAT5 is assessed in Ba/F3 cells stably expressing EPOR
1J.
concentrations CHZ868 (mM) relative to proliferation in presence of DMSO is
sented as mean ± SEM. IC50 values represent the mean of two independent
concentrations ruxolitinib (mM) relative to proliferation in presence of DMSO is
sented as mean ± SEM. IC50 values represent the mean of two independent
V617F and EPOR JAK2WT Ba/F3 cells. Data are represented as mean ± SEM,
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Table 1. Cross-Persistence to Type I JAK Inhibitors
JAK Inhibitor IC50 Naive IC50 Ruxper IC50 CYT387per IC50 SAR302503per IC50 BMS911543per
Ruxolitinib 0.07 0.90 0.47 0.82 1.0
CYT387 0.17 4.2 1.3 1.7 3.0
SAR302503 0.41 2.3 1.5 1.6 1.3
BMS911543 0.26 6.5 1.6 1.9 3.4
Indicated IC50s (mM) are derived from proliferation assays in SET2 cells.STAT3, STAT5, or ERK1/2 phosphorylation in persistent cells
(Figure S1E), consistent with a lack of target inhibition. Gene
set enrichment analysis (GSEA) demonstrated significant
enrichment of an activated STAT5 gene expression signature
(Schuringa et al., 2004) in persistent cells (Figures 1B and
S1F). We also observed reduced expression of apoptosis
gene expression signatures, consistent with the increased
survival of persistent cells (Figures 1C and S1G). Principal
component analysis (PCA) of RNA-sequencing data separated
type I JAK inhibitor persistent cells from naive cells based
on differential gene expression (Figures S1H and S1I). We did
not identify acquired mutations in JAK2, JAK1, or TYK2 in
any of the persistent lines, and persistence to CYT387,
BMS911543, and SAR302503 was reversible after drug with-
drawal (data not shown).
We next investigated whether activated JAK2 interacted
with JAK1 or TYK2 in CYT387, BMS911543, and SAR302503
persistent cells, as shown previously for ruxolitinib persistence
(Koppikar et al., 2012). We observed increased association of
phosphorylated JAK2 and JAK1/TYK2 in JAK inhibitor persistent
cells (Figure S1J), and heterodimer formation increased over
time (Figure S1K). Immunofluorescence confirmed heterodimers
were localized near the plasma membrane in CYT387 and ruxo-
litinib persistent cells (Figure S1L), and we observed JAK1-JAK2
co-localization in persistent cells (Figures S1M and S1N). MPN
cells that acquired persistence to a specific type I JAK inhibitor
were cross-persistent to all other type I JAK inhibitors (Figure 1D;
Table 1). These data demonstrate that type I JAK inhibitors in
clinical development cannot overcome persistence induced by
another type I inhibitor.
Type II Inhibition with CHZ868 Demonstrates Efficacy in
JAK2 and MPL Mutant MPN Cells
A previous study reported that BBT594, a type II kinase inhibitor
designed to inhibit the BCR-ABL T315I resistance allele, had sig-
nificant activity in JAK-dependent cellular assays (Andraos et al.,
2012). However, this agent was limited in potency, specificity,
and pharmacokinetic properties for in vivo assessments. Our
drug discovery efforts focusing on chemical scaffolds known
to stabilize kinases in their inactive (type II) conformation led to
the discovery of a benzimidazole analog, CHZ868 (cf. the
accompanying submission by Wu et al., 2015 in this issue of
Cancer Cell). CHZ868 potently inhibited constitutive JAK2 and
STAT5 phosphorylation in JAK2V617F SET2 cells (Figure S1O),
whereas 5- to 10-fold higher CHZ868 concentrations were
required to suppress constitutive JAK3 and STAT5 phosphoryla-
tion in JAK3A572V mutant CMK cells (Figure S1P). Consistent
with the notion that CHZ868 has a bias to inhibit JAK2 over
JAK3, CHZ868 potently inhibited the proliferation of SET2 cells18 Cancer Cell 28, 15–28, July 13, 2015 ª2015 Elsevier Inc.(GI50 = 59 nM) and had 6-fold less growth inhibitory activity
against CMK cells (GI50 = 378 nM). In contrast to BBT594,
CHZ868 lacked activity against BCR-ABL as demonstrated
by insensitivity of K562 cells (GI50 = 4627 nM) (Figure S1Q).
To assess cellular activity against JAK1 and TYK2, we first
assessed the impact of CHZ868 on nuclear translocation
of STAT1 upon stimulation of HT1080 cells with INF-a. We
observed a 60- to 70-fold higher IC50 for inhibition of JAK1-/
TYK2-mediated nuclear STAT1 translocation by CHZ868 com-
pared with pan-JAK inhibitor tofacitinib (Figures S1R and S1S).
CHZ868 suppressed JAK1 and TYK2 signaling in INF-a stimu-
lated TF-1 cells at 10-fold higher concentrations than JAK2
signaling in SET2 cells (Figure S1T). Moreover, CHZ868 showed
less potent ability to inhibit the proliferation of isogenic Ba/F3
cells stably expressing constitutively active JAK1 V658F and
TYK2 V678F compared with cells expressing JAK2 V617F; we
observe growth inhibition at 4- and 24-fold higher IC50 values,
respectively, as compared with JAK2 V617F (Figure 1E). These
results demonstrate that CHZ868 most potently inhibits JAK2
among the JAK kinases.
Next, we assessed the activity of CHZ868 toMPLmutant cells
in vitro. As in SET2 cells, CHZ868 potently inhibited the prolifer-
ation of 32D cells expressing MPLW515L (Figures 1F and 1G).
CHZ868 treatment abrogated phosphorylation of Y1007/Y1008
in the JAK2 activation loop, consistent with a type II mechanism
of action (Figures 1H and S1O). In contrast, ruxolitinib exposure
led to JAK2 stabilization and persistent activation loop phos-
phorylation (Figure 1H) (Andraos et al., 2012). Inhibitor washout
studies confirmed that phosphorylation of JAK2 and STAT5
was gradually restored within 4–24 hr after removing CHZ868
(Figure S1U). CHZ868 potently induced apoptosis in JAK2 and
MPLmutant cells, as reflected by caspase 3 activation (Figure 1I)
and by annexin V staining (Figure S1V), and exhibited enhanced
killing of JAK2V617F SET2 cells comparedwith ruxolitinib. These
findings demonstrate that type II JAK2 inhibition with CHZ868
shows significant activity in JAK2V617F andMPLW515L mutant
cells, including potent inhibition of JAK2 and STAT phosphoryla-
tion and induction of cell death.
We further investigated the sensitivity of mutant versus WT
JAK2 to CHZ868 in Ba/F3 cells stably expressing JAK2 V617F
or JAK2 WT co-expressed with the erythropoietin receptor
(EPOR), using EPO to activate EPOR/JAK2 signaling in WT cells.
CHZ868 suppressed the phosphorylation of STAT3 and STAT5
at 2- to 3-fold lower concentrations in JAK2 V617F than in
JAK2 WT cells (Figures 1J and 1K). Concordant with effects on
signaling, CHZ868 more potently inhibited the proliferation of
JAK2 V617F cells, with IC50 values 2- to 3-fold lower than the
growth of JAK2 WT cells (IC50 JAK2 V617F 0.06 mM, JAK2 WT
0.17 mM; Figure 1L). In contrast, we saw equivalent growth
inhibitory activity of ruxolitinib in JAK2 V617F and WT cells (Fig-
ure 1M). These findings demonstrate that type II JAK2 inhibition
with CHZ868 shows increased relative activity against JAK2
V617F versus JAK2 WT cells (Figure 1N).
Type II JAK Inhibition by CHZ868 Overcomes
Persistence to Type I JAK Inhibitors
We next investigated whether CHZ868 could inhibit JAK-STAT
signalingandattenuateproliferationof type I JAK inhibitor-persis-
tent cells. CHZ868 exposure led to potent, concentration-depen-
dent inhibition of JAK2 phosphorylation in CYT387, BMS911543,
and ruxolitinib persistent cells (Figure 2A). CHZ868 treatment
abrogated STAT3 and STAT5 phosphorylation in persistent cells,
whereas type I JAK inhibitors had no effect on signaling. Concor-
dant with the signaling data, CHZ868 exposure led to concen-
tration-dependent inhibition of proliferation of JAK2V617F or
MPLW515L cells that were insensitive to CYT387, SAR302503,
BMS911543, and ruxolitinib (Figures 2B and S2). The IC50 to
CHZ868 was 5- to 16-fold lower compared with the IC50 for
type I inhibitors in persistent SET2 or 32D MPLW515L cells and
was similar to the IC50 observed in inhibitor naivecells (Figure 2C).
CHZ868 exposure led to a concentration-dependent increase in
apoptosis in ruxolitinib (Figure 2D), BMS911543 (Figure 2E), and
CYT387 (not shown)persistent cells,whereasexposureof persis-
tent cells to type I inhibitors did not induce significant apoptosis.
To elucidate the mechanism by which CHZ868 reverses inhib-
itor persistence, we performed co-immunoprecipitation studies
with JAK1 or TYK2 followed by western blot analysis of JAK2
phosphorylation at the Y1007/Y1008 tandem tyrosine in the acti-
vation loop. Consistent with the western blot studies for phos-
phorylated JAK2, we did not observe any phosphorylated
JAK2 bound to JAK1 or TYK2 in persistent cells cultured in the
presence of CHZ868 (Figure 3A). The loss of activated JAK2
bound to JAK1 and TYK2was sustained, with complete absence
of JAK2 activation loop phosphorylation after 20 hr of CHZ868
exposure, suggesting type II inhibition durably abolishes JAK2
activation (Figure 3B). As CHZ868 did not inhibit dimerization be-
tween unphosphorylated JAK2 and JAK1/TYK2, we investigated
how CHZ868 interfered with transphosphorylation of JAK2 by
JAK1/TYK2 in heterodimers. Given the bias of CHZ868 toward
inhibition of JAK2 over JAK1 and TYK2 (Figure 1E), we hypothe-
sized that type II inhibition restricted accessibility of JAK2 for
transphosphorylation by stabilizing JAK2 in the inactive form.
We expressed constitutively active JAK1 V658F and kinase-
dead JAK2 K882E in g2A cells deficient of endogenous JAK2,
such that all JAK2 activation occurs in trans by activated JAK1.
CHZ868 abrogated JAK1-mediated Y1007/Y1008 phosphoryla-
tion of JAK2 K882E at concentrations that did not fully inhibit
JAK1 autophosphorylation (Figure 3C). This finding demon-
strated that type II inhibition by CHZ868 attenuates JAK2 trans-
phosphorylation in heterodimers by inhibiting JAK1 activity and
by restricting accessibility of JAK2 for transphosphorylation at
the activation loop.
We next evaluated the impact of CHZ868 on other phosphor-
ylation sites known to be involved in the regulation of JAK2
kinase activity. We assessed the ability of CHZ868 to impact
JAK1-mediated phosphorylation of Y221, which has a known
activating role for JAK2 (Argetsinger et al., 2004). Concordant
with suppressed phosphorylation at Y1007/Y1008, CHZ868 in-hibited phosphorylation at Y221 in type I JAK inhibitor persistent
cells (Figure 3D, top row). In contrast, CHZ868 did not alter the
phosphorylation of Y570 and S523, which are implicated in
negative regulation of JAK2 activity (Argetsinger et al., 2004;
Bandaranayake et al., 2012; Ungureanu et al., 2011) (Figure 3D,
middle and bottom row). These findings suggest that type II JAK
inhibition with CHZ868 renders activating phospho sites of JAK2
not (Y1007/Y1008) or less (Y221) accessible for transphosphor-
ylation in heterodimers, whereas phosphorylation of inhibitory
sites in the JH2 domain remains intact, which overall results in in-
hibition of JAK2 activity and suppression of JAK-STAT signaling
in type I inhibitor persistent cells.
To investigate the impact of CHZ868 on type I inhibitor persis-
tence in vivo, we treated C3H/HeJ mice engrafted with Ruxper
32D MPLW515L cells (Figures S3A and S3B). Vehicle-treated
animals succumbed to disease within 20 days of transplantation
with splenomegaly (Figures S3C and S3D) and hepatomegaly
(Figure S3E), infiltration of bone marrow (Figure S3B), lung,
and liver (Figures S3F and S3G). Treatment with CHZ868 at
40 mg/kg once daily normalized splenomegaly within 7 days of
treatment (Figures S3C and S3D) and reduced leukemic infiltra-
tion of lung and liver (Figures S3F and S3G). CHZ868 significantly
prolonged survival of C3H/HeJ mice transplanted with Ruxper
32D MPLW515L cells (Figure S3H).
We next assessed the effect of CHZ868 on inhibition of JAK2
signaling in primary samples from ruxolitinib treatedMF patients.
In line with previous reports (Bhagwat et al., 2014; Koppikar
et al., 2012), we observed pronounced activation of STAT3 and
STAT5 in peripheral blood mononuclear cells from MF patients
receiving chronic ruxolitinib therapy. In contrast, CHZ868
completely suppressed phosphorylation of STAT3 and STAT5
(Figure 3E). We observed dose-dependent inhibition of pSTAT3
and pSTAT5 with strong inhibitory effects at low concentrations
(Figure 3F). These data demonstrate that CHZ868 inhibits JAK-
STAT signaling inMPN patient cells, which persist during chronic
ruxolitinib treatment.
CHZ868 Shows Significant Efficacy in
Jak2V617F-Driven PV
We next assessed the efficacy of CHZ868 at inhibiting myelo-
proliferation in vivo. We first used Jak2V617F conditional
knock-in mice (Mullally et al., 2010) crossed with a Vav-cre allele
to express Jak2V617F in the hematopoietic compartment. We
transplanted CD45.2 Jak2V617F and CD45.1 Jak2 WT cells
into CD45.1 recipients to allow us to assess the impact of
CHZ868 on the mutant clone in vivo compared with WT cells.
CHZ868 dosed at 30–40 mg/kg orally once daily inhibited JAK-
STAT signaling in vivo consistent with potent target inhibition
(Figure 4A). CHZ868 therapy resulted in significant reduction in
the proportion of mutant cells in the bone marrow (Figure 4B).
We also observed a significant decrease of mutant allele burden
in the CD71+Ter119+ erythroid progenitor compartment with
CHZ868 as compared with vehicle-treated mice (Figure 4C),
consistent with a mutant-biased reduction in erythroid output.
These data demonstrate that type II JAK2 inhibition with
CHZ868 reduces mutant allele burden in vivo, which we and
others have not observed with type I inhibitors in preclinical
models (Kubovcakova et al., 2013; Mullally et al., 2010; Tyner
et al., 2010).Cancer Cell 28, 15–28, July 13, 2015 ª2015 Elsevier Inc. 19
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Figure 2. Type II JAK2 Inhibition by CHZ868 in Persistence to Type I JAK Inhibitors
(A) Effect of 4 hr incubation with increasing concentrations of CHZ868 or with the respective type I JAK inhibitor on phosphorylation of JAK2, STAT3, and STAT5 in
CYT387 (CYTper), BMS911543 (BMSper), or ruxolitinib (Ruxper) persistent SET2 cells.
(B) Proliferation of CYT387 (CYTper), SAR302503 (SARper), BMS911543 (BMSper), or ruxolitinib (Ruxper) persistent SET2 cells upon increasing concentrations of
the respective type I JAK inhibitor or CHZ868 relative to proliferation in the presence of DMSO. All data are represented as mean ± SEM.
(legend continued on next page)
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Figure 3. Effect of Type II JAK2 Inhibition with CHZ868 on Transphosphorylation of JAK2 in Heterodimers
(A) The phosphorylation at Y1007/Y1008 of JAK2 co-immunoprecipitated with JAK1 (left) or TYK2 (right) is shown after 4 hr incubation of CYT387 (CYTper) and
ruxolitinib (Ruxper) persistent SET2 cells with CHZ868 or DMSO as control.
(B) The phosphorylation at Y1007/Y1008 of JAK2 is also assessed after 20 hr incubation with CHZ868 or DMSO as control.
(C) Phosphorylation of JAK2 at Y1007/Y1008 and phosphorylation of JAK1 are assessed in g2A cells deficient of endogenous JAK2 and stably expressing
constitutively active JAK1 V658F and kinase dead JAK2 K882E after 4 hr exposure to CHZ868.
(D) Phosphorylation at Y221 of JAK2 (top row) co-immunoprecipitated with JAK1 (left) or TYK2 (right) as well as phosphorylation at Y570 (middle row) and at S523
(bottom row) are shown after 4 hr incubation with CHZ868.
(E) Phosphorylation of STAT3 and STAT5 in freshly isolated peripheral bloodmononuclear cells fromMPN patients on long-term ruxolitinib treatment is assessed
after 16 hr ex vivo exposure with CHZ868.
(F) STAT3 and STAT5 phosphorylation in freshly isolated peripheral blood mononuclear cells from a chronically ruxolitinib treated MPN patient is also assessed
after 16 hr ex vivo exposure with increasing concentrations of CHZ868.
See also Figure S3.Consistent with the effects on disease burden, CHZ868
normalized spleen and liver weights, demonstratingmarked inhi-
bition of extramedullary hematopoiesis (Figure 4D). Peripheral
blood count analysis showed that CHZ868 reduced hematocrit
from 71% in vehicle-treated mice to 51.1% and 49.4% with(C) IC50 values for CHZ868 in CYT387, SAR302503, BMS911543, and ruxolitinib p
IC50 values of the respective type I JAK inhibitors. Data are represented as mean
(D) Induction of apoptosis with increasing concentrations of CHZ868 or ruxolitinib
representative flow cytometry histograms (left) and as mean ± SEM (right).
(E) Induction of apoptosis with increasing concentrations of CHZ868 or BMS9115
(left) and as mean ± SEM (right).
See also Figure S2.30 and 40 mg/kg CHZ868, respectively (Figure 4E). CHZ868
therapy normalized the modestly elevated white blood cell
count seen in the Jak2V617F model of PV. Histopathologic
analysis demonstrated CHZ868 therapy restored normal splenic
architecture, in contrast to the myelo-erythroid infiltrationersistent JAK2V617F SET2 andMPLW515L 32D cells are shown relative to the
± SEM.
in Ruxper SET2 cells is shown by the proportion of caspase-3-positive cells in
43 in BMSper SET2 cells is shown in representative flow cytometry histograms
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Figure 4. Type II JAK2 Inhibition by CHZ868 In Vivo in the Conditional Jak2V617F Knock-in Model of PV
(A) JAK2 and STAT5 phosphorylation are assessed after 14 days of treatment with 30 and 40 mg/kg CHZ868 in the conditional Jak2V617F knock-in
model of PV.
(legend continued on next page)
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observed in vehicle-treated animals (Figure 4F). CHZ868 therapy
reduced the bone marrow megakaryocytic hyperplasia seen in
vehicle-treated mice (Figure 4G). The expansion of erythroid
progenitors characteristic of Jak2V617F knock-in bone marrow
was significantly reduced with CHZ868 therapy. We observed
significantly reduced erythroid progenitors with type II Jak2 inhi-
bition, including CD71+Ter119+ proerythroblasts (Figure 4H,
p = 0.036 and p = 0.015), LincKithighCD41FcgRCD150+
CD105+ Pre-CFUE (p < 0.01 and p < 0.001), and
LincKithighCD41FcgRCD150+CD105 Pre-MegE (p = 0.02
and p < 0.01), as described (Pronk et al., 2007) (Figures 4I and
4J). CHZ868 also decreased the proportion of myelo-erythroid
progenitors, including LinSca1Kit+ multipotent myeloid pro-
genitors (Figures 4J and 4K, p = 0.02).
We performed additional studies in a second model of PV-like
disease, in which mice were engrafted with bone marrow retro-
virally transduced with Jak2V617F-IRES-GFP. Consistent with
the efficacy of CHZ868 in the Jak2V617F conditional knock-in
model, CHZ868 at 30 mg/kg orally once daily completely re-
verted splenomegaly and reduced hematocrit, reticulocyte,
and white blood cell (WBC) counts (Figures S4A–S4D). We
observed a significant reduction in mutant allele burden with
CHZ868 therapy also in the retroviral Jak2V617F transplant
model, as reflected by a reduction in the proportion of circulating
GFP+ cells (Figure S4E). Consistent with the effect on disease
burden, CHZ868 therapy inhibited phosphorylated STAT5, as
assessed by IHC in spleen and bone marrow (Figures S4F and
S4G). Furthermore, histopathology assessment revealed that
CHZ868 therapy resulted in decreased splenic erythro- and
myeloproliferation, decreased bone marrow hypercellularity
(Figure S4H, top and middle), and a reduction of reticulin fiber
deposits (Figures S4H and S4I).
Efficacy of CHZ868 in MPLW515L-Induced MF
We next assessed the efficacy of CHZ868 in a murine model of
PMF-like disease.We used the retroviral bonemarrow transplant
(BMT) model of MPLW515L-induced MF, which leads to a fully
penetrant, lethal MPN characterized by severe MF (Koppikar
et al., 2010). CHZ868 completely suppressed STAT5 and
STAT3 phosphorylation (Figure 5A). JAK2 phosphorylation was
also reduced, consistent with the type II binding mode of(B) Allele burden as reflected by CD45.2 donor chimerism in primary recipients of
and 40 mg/kg CHZ868 relative to vehicle-treated mice (n = 6–7 mice/group, dat
(C)Mutant allele burden is at 60.4%and 39.0% in recipients of Jak2V617F knock-i
mice specifically in the CD71+Ter119+ erythroid progenitor compartment. Data a
(D) Spleen size and weight as well as liver weight at 14 days of treatment wit
age-matched control mice. Data are represented as mean ± SEM (*p < 0.05, ***p
(E) Hematocrit (Hct) at 14 days of treatment with CHZ868 30 or 40 mg/kg. Data ar
(F) Splenic architecture and the extent of myelo-erythroid infiltration of the splee
(G) Bone marrow histology with a particular focus on megakaryocyte number is
(H) The CD71+Ter119+ proerythroblast population in vehicle- and CHZ868-treate
p = 0.015 at 30 and 40 mg/kg CHZ868 versus vehicle group, respectively).
(I) LincKithighCD41FcgRCD150+CD105+ committed erythroid progenitors (P
yocyte-erythroid progenitors (Pre-MegE) are assessed as described (Mullally et
(Pre-CFUE p < 0.01 and p < 0.001; Pre-MegE p = 0.02 and p < 0.01 versus vehi
(J) Myeloerythroid progenitor frequencies including multipotent myeloid progen
committed erythroid progenitors (Pre-CFUE) after treatment with CHZ868 30 and
represented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle g
(K) Representative flowcytometryplots are shown for LinSca1Kit+multipotentm
See also Figure S4.CHZ868. CHZ868-mediated inhibition of JAK-STAT signaling
was maintained with 10 days of treatment consistent with
chronic, potent target inhibition (data not shown). CHZ868 ther-
apy significantly improved survival of mice with MPLW515L-
induced MF (Figure 5B, p < 0.0001, 10–11 mice per arm) and
resulted in dose-dependent reduction of hepatomegaly (Fig-
ure 5C) and normalization of spleen weight and size with
40 mg/kg CHZ868 (Figure 5D). CHZ868 dose dependently
reduced extramedullary hematopoiesis in liver and spleen, with
complete restoration of liver/spleen tissue architecture in the
40mg/kg arm (Figure 5E). CHZ868 reduced bonemarrowmega-
karyocytosis (Figure 5E) and bone marrow and spleen hypercel-
lularity (Figure S5A), features characteristic of MPLW515L-
induced MF. CHZ868 therapy resulted in dose-dependent
reduction in MPLW515L-induced leukocytosis (p = 0.035) and
thrombocytosis (p < 0.01), consistent with CHZ868-mediated
inhibition of myeloproliferation (Figure 5F). In addition to
MPLW515L-induced MF in Balb/C mice, therapeutic effects of
CHZ868 were confirmed in C57BL/6 mice using theMPLW515L
BMT model (Figures S5B–S5D) to enable flow cytometric anal-
ysis of progenitor populations. CHZ868 therapy resulted in a
trend toward reduced proportions of LinSca1Kit+ multipotent
myeloid progenitors and LinSca1Kit+FcgRCD34 megakar-
yocytic-erythroid progenitor populations (Figures 5G and 5H).
Importantly, CHZ868 therapy markedly decreased bone marrow
and spleen reticulin fibrosis, consistent with disease-modifying
activity (Figures 5I and S5E). In addition, CHZ868 therapy signif-
icantly reduced mutant allele burden, as reflected by a reduction
in the proportion of GFP+ cells in peripheral blood (Figure 5J,
p = 0.017).
As we observed significant reductions of mutant allele burden
not observed with type I inhibitors in these MPN models, we
investigated whether CHZ868 had differential cytotoxic effects
on bone marrow hematopoietic progenitors. We used immuno-
fluorescent staining for cleaved caspase-3 in the MPLW515L
model and flow cytometric analyses of annexin V positivity in
theMPLW515L and the Jak2V617F knock-in models after in vivo
treatment with CHZ868. CHZ868 strongly reduced MPLW515L
GFP+ megakaryocytes in bone marrow and spleen, and induced
apoptosis in vivo (Figure S5F). We observed an increase in
MPLW515L GFP/cleaved Caspase-3 double-positive cellsJak2V617F knock-in bone marrow is shown after 14 days of treatment with 30
a represented as mean ± SEM, **p < 0.01 versus vehicle group).
n bonemarrow treatedwith 30 and 40mg/kg CHZ868 relative to vehicle-treated
re represented as mean ± SEM (*p < 0.05, **p < 0.01 versus vehicle group).
h CHZ868 30 or 40 mg/kg. The dashed line indicates the spleen weight of
< 0.001 versus vehicle group).
e represented as mean ± SEM (**p < 0.01 or ***p < 0.001 versus vehicle group).
n are shown in vehicle-treated as compared with CHZ868-treated animals.
shown in vehicle- and CHZ868-treated mice.
d animals is illustrated by representative flow cytometry plots (p = 0.036 and
re-CFUE) and LincKithighCD41FcgRCD150+CD105 bipotential megakar-
al., 2010; Pronk et al., 2007) after treatment with 30 and 40 mg/kg CHZ868
cle group, respectively), and representative flow cytometry plots are shown.
itors (MP), bipotential megakaryocyte-erythroid progenitors (Pre-MegE), and
40 mg/kg for 14 days are indicated relative to vehicle-treated animals. Data are
roup).
yeloid progenitors in thepresence andabsenceofCHZ868 treatment (p =0.02).
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Figure 5. Type II JAK2 Inhibition by CHZ868 In Vivo in the MPLW515L Model of MF
(A) Phosphorylation of JAK2, STAT3, and STAT5 is evaluated after three doses of CHZ868 at 30 or 40 mg/kg in the MPLW515L model.
(B) Survival in the MPLW515L model of MF upon long-term treatment with CHZ868 (p < 0.0001, 10–11 mice/arm).
(legend continued on next page)
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compared with MPL WT GFP- megakaryocytes (arrowheads)
consistent with increased susceptibility for apoptosis induction
by CHZ868 in the mutant compartment. Concordant with this
observation, flow cytometric analysis of annexin V positivity
showed that CHZ868 induced increased apoptosis in
MPLW515L versus MPL WT and in Jak2V617F versus Jak2 WT
LinSca1Kit+ multipotent myeloid progenitors (Figures S5G
and S5H). These findings show that type II JAK inhibition induces
apoptosis in vivo on mutant, MPN progenitors and suggest
type II JAK2 inhibition may represent an approach to target the
malignant clone in MPNs.
DISCUSSION
Genetic and functional studies have shown that constitutive JAK
signaling is a pathogenetic feature of classical MPN, mostly due
to activating mutations in JAK2 itself, or less commonly due to
mutations in MPL, LNK (Tong et al., 2005), or CBL (Schwaab
et al., 2012). These insights have underscored the development
of JAK inhibitors and the clinical use of ruxolitinib for the treat-
ment of MPN patients. Despite the significant benefits offered
by ruxolitinib (Harrison et al., 2012; Verstovsek et al., 2012), the
lack of molecular or pathologic responses with chronic JAK in-
hibitor therapy has suggested that there are limits to the efficacy
of type I JAK inhibitors. Here we show that type II JAK2 inhibition
with CHZ868 can reverse type I JAK inhibitor persistence and
can reduce disease burden in preclinical MPN models.
The development of ruxolitinib encouraged studies on a class
of ATP-competitive JAK inhibitors, which stabilize JAK2 in the
active conformation. Additional type I JAK inhibitors with
slightly different kinase specificities are in late-stage clinical
development. CYT387, a JAK1 and JAK2 inhibitor similar to
ruxolitinib with additional activity against TBK1 and IKKε (Zhu
et al., 2014), is being evaluated in phase 2 and phase 3 trials
of MF and PV, while BMS911543, a selective JAK2 inhibitor,
is in a phase 1/2 study. The clinical trials with the JAK2/FLT3
inhibitor SAR302503 were recently halted due to CNS toxicity.
These additional type I JAK inhibitors may provide further ther-
apeutic options for MPN patients, including those who fail or
cannot tolerate ruxolitinib therapy. However, we observed
that despite being highly active in naive MPN cells, the different
type I inhibitors elicit persistence through the same mechanism
of heterodimeric JAK2 activation that we previously described
for ruxolitinib. Moreover, we found that cells cultured in the(C) Liver weight in animals treated for 10 days with CHZ868 at 30 or 40 mg/kg v
versus vehicle group).
(D) Spleen weight (left) and size (right) upon 10 days treatment with CHZ868 30 or
in age-matched controls. Spleen weights are represented as mean ± SEM (**p <
(E) The extent of extramedullary hematopoiesis in the liver (top row) and myelo
hyperplasia of the bone marrow (bottom row) are shown after 10 days of treatme
(F) Peripheral blood WBC and platelet (Plts) counts are indicated for CHZ868-
(*p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle group).
(G) LinSca1Kit+ multipotent myeloid progenitors (MP) of CHZ868- and vehicle
(H) The impact of CHZ868 treatment on LinSca1Kit+FcgRCD34 megakaryo
(I) The impact of 10 daysCHZ868 treatment on reticulin fibrosis, which represents
marrow (BM, top row) and spleen (Sp, bottom row).
(J) Mutant allele burden as reflected by the percentage of GFP+ cells in periphe
represented as mean ± SEM (*p < 0.05 versus vehicle group).
See also Figure S5.presence of CYT387, BMS911543, or SAR302503 were
cross-persistent to all other type I JAK inhibitors, including
ruxolitinib. These findings suggest that additional mechanisms
of JAK inhibition should be explored to improve efficacy in pa-
tients who do not derive sufficient clinical benefit from chronic
ruxolitinib therapy.
The limitations of type I JAK inhibitors in the clinic have
prompted investigations of resistance to these agents. Several
groups have identified second-site JAK2mutations in saturation
mutagenesis screens performed in the presence of type I JAK
inhibition, but these mutations have not been identified in MPN
patients (Deshpande et al., 2012; Weigert et al., 2012). These
data strongly suggest that the limited therapeutic efficacy of
type I JAK2 inhibitors is due to insufficient target inhibition and
not due to genetic resistance. Recent studies have suggested
that combining JAK inhibitors with inhibition of key downstream
pathways, such as PI3K/Akt, might increase therapeutic efficacy
and are now being explored in preclinical models and clinically
(Fiskus et al., 2013). In addition, we and others have recently
shown that combined JAK2 and HSP90 or HDAC inhibition
shows increased efficacy in vivo (Bhagwat et al., 2014; Evrot
et al., 2013; Marubayashi et al., 2010). However, these ap-
proaches require investigation of combinations and may result
in increased toxicity due to inhibition of multiple, essential
cellular pathways.
We therefore investigated the efficacy of type II JAK2 inhibition
with CHZ868, which binds JAK2 in the inactive conformation in
contrast to type I inhibitors that bind JAK2 in the active form.
CHZ868 had similar efficacy in type I JAK inhibitor naive and
persistent cells and a bias toward inhibition of mutant JAK2
V617F over WT JAK2, consistent with a different mechanism of
JAK kinase inhibition. We observed potent suppression of JAK
signaling, proliferation, and induction of apoptosis in MPN cells
by CHZ868 regardless of previous exposure to type I JAK inhib-
itors. These data demonstrate that type I JAK inhibitor persistent
cells remain sensitive to type II JAK inhibitors and that CHZ868
retains therapeutic efficacy in cells that acquire insensitivity to
clinically utilized JAK inhibitors. We hypothesized that the mech-
anism by which type II inhibition abrogates cross-persistence re-
lates to the stabilization of JAK2 in the inactive conformation.
This may occur by blocking JAK2monomers in the inactive state
and shifting the equilibrium away from JAK heterodimers, which
contain the active form of the kinase. Alternatively, type II inhibi-
tion might overcome cross-persistence by directly inhibitingersus vehicle treatment. Data are represented as mean ± SEM (****p < 0.0001
40 mg/kg versus vehicle-treated mice. The dashed line indicates spleen weight
0.01, ***p < 0.001 versus vehicle group).
erythroid infiltration of the spleen (middle row) as well as of megakaryocytic
nt with CHZ868 30 or 40 mg/kg versus vehicle treatment.
and vehicle-treated MPLW515L mice. Data are represented as mean ± SEM
-treated MPLW515L mice are shown in representative flow cytometry plots.
cytic-erythroid progenitors (MEP) in the MPLW515L model is also assessed.
a hallmark of theMPLW515Lmodel ofMF, is assessed by silver staining of bone
ral blood is shown at 10 days of treatment with CHZ868 40 mg/kg. Data are
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JAK2 in the heterodimers. CHZ868 promptly inactivated JAK2
incorporated in JAK heterodimers, and JAK-STAT signaling
was simultaneously abrogated without a requirement for hetero-
dimer dissociation. Concordant with a bias toward inhibition of
JAK2 over JAK1 and TYK2, CHZ868 suppressed transphos-
phorylation of kinase-dead JAK2 at the activation loop, suggest-
ing that CHZ868 renders the JAK2 activation loop inaccessible
for transphosphorylation. We found a differential interference
of CHZ868 with inhibition of activating phosphorylation events
at Y1007/Y1008 and at Y221 and preserved phosphorylation at
regulatory sites in the pseudokinase domain at Y570 and
S523, resulting in a net profound inhibition of heterodimeric
JAK2. These findings suggest that inactivation of heterodimeric
JAK2 by type II inhibition involves differential changes in the
accessibility of functionally different phospho sites interfering
with transactivation.
Consistent with the in vitro data, in preclinical models of
Jak2V617F-induced PV and MPLW515L-induced MF, CHZ868
treatment reversed MPN hallmarks, including splenomegaly,
pathologic erythrocytosis, thrombocytosis, and leukocytosis
and alterations in bone marrow progenitor populations induced
by constitutive Jak2 or MPL mutant alleles. CHZ868 therapy
attenuated reticulin fibrosis, a key pathologic MF trait that per-
sists with chronic type I JAK inhibitor therapy. Most importantly,
CHZ868 therapy induced a significant decrease in mutant allele
burden in preclinical models of PV and MF based on an
increased susceptibility of Jak2V617F and MPLW515L cells
to CHZ868 in vitro and in vivo. The molecular and histologic
responses seen with CHZ868 therapy suggest a disease-modi-
fying effect of type II JAK inhibition in MPN, similar to that
observed with CHZ868 in JAK2R683G mutated B-ALL models
(cf. the accompanying manuscript by Wu et al., 2015).
Although subsequent preclinical and clinical studies are
needed to delineate efficacy and toxicity of type II JAK inhibition,
these data suggest that alternate mechanisms of kinase inhibi-
tion can increase therapeutic benefit. We anticipate that similar
approaches for other mutated kinases might offer similar benefit
in other malignant contexts. Most importantly, our data demon-
strate that current approaches to target JAK2 have not fully
tested the dependency for JAK2 kinase activity in the clinical
contexts and suggest the need to explore additional approaches
to improve target inhibition in themalignant clone and to improve
outcomes for patients with MPNs, as well as with other malig-
nancies characterized by activated JAK2 signaling.
EXPERIMENTAL PROCEDURES
Inhibitors
CHZ868 was synthesized by Novartis and stored at 1 mM in DMSO for in vitro
use. For in vivo applications, CHZ868 was administered orally at 15 mg/kg
twice daily (bid) or at 15, 20, 30, or 40 mg/kg once daily (qd). CYT387,
BMS911543, and ruxolitinib were purchased from Chemietek. SAR302503
was synthesized as described (Marubayashi et al., 2010); these agents were
stored at 1 mM in DMSO at 20C.
Cell Lines
SET2 cells were cultured in RPMI1640/20% fetal calf serum (FCS). 32D and
TF-1 cells were transduced with viral supernatants containing MSCV-
hMPLW515L-IRES-GFP (Pikman et al., 2006), FACS sorted for GFP and
cultured in RPMI1640/10% FCS. A panel of SET2, 32D MPLW515L, and
TF-1 MPLW515L cell lines persistent to CYT387, BMS911543, SAR302503,26 Cancer Cell 28, 15–28, July 13, 2015 ª2015 Elsevier Inc.or ruxolitinib were generated by culture in presence of increasing inhibitor
concentrations for 8–10 weeks. Resensitization was induced by drug with-
drawal. Ba/F3 cells stably expressing JAK2 V617F/EPOR were cultured in
RPMI1640/10% FCS, supplemented with 10 U/ml EPO in case of Ba/F3 cells
expressing JAK2 WT/EPOR. Ba/F3 cells stably expressing TYK2 V678F
(generously provided by S. Constantinescu) or JAK1 V658F were cultured in
RPMI1640/10% FCS. g2A cells deficient of endogenous JAK2 and stably ex-
pressing JAK1 V658F and JAK2 K882E were maintained in Dulbecco’s modi-
fied Eagle’s medium (DME)/10% FCS.
In Vitro Inhibitor Assays
To assess anti-proliferative effects of inhibitors, all cell lines were cultured
at 10,000 cells/200 ml with increasing inhibitor concentrations in triplicate. Pro-
liferation was assessed at 48 hr using the cell viability luminescent assay
(Promega) and normalized to cell growth in media with an equivalent volume
of DMSO (Koppikar et al., 2010). The concentration inhibiting proliferation by
50% (IC50) was determinedwith Graph PadPrism5.0. Anti-proliferative activity
of inhibitors in SET2, CMK, and K562 cells was also determined by incubation
for 72 hr and proliferation measured by colorimetric WST-1 cell viability
readout (Roche). Of each triplicate, the mean was calculated, and data were
plotted in XLfit 4 (ID Business Solutions) to determine half-maximal growth in-
hibition (GI50).
Transcriptional Profiling, GSEA, and PCA
SET2 cells were treated with ruxolitinib at 0.7 mM for 4 hr, left untreated, or in
case of the type I inhibitor persistent SET2 cells, chronically cultured in pres-
ence of CYT387, BMS911543, SAR302503, or ruxolitinib. Triplicate samples
were lysed in TRIzol (Life Technologies). Please see Supplemental Experi-
mental Procedures for details on sequencing and expression analysis.
Induction of Apoptosis
Naive or type I JAK inhibitor persistent cells were cultured for 24 hr at
106 cells/ml with increasing inhibitor concentrations, washed twice in ice-
cold PBS, and assessed for apoptosis induction by CASPASE-3 MAB
APOPTOSIS KIT (BD) or by Annexin V PE apoptosis kit (BD) and flow cytometry
on LSRFortessa (BD).
JAK Signaling and Heterodimer Formation
Cells were incubated at 106/ml media with inhibitor or DMSO for 4 hr, washed
in ice-cold PBS, and collected in lysis buffer with Protease Arrest (G-Biosci-
ences) and Phosphatase Inhibitor Cocktail II (EMD). Ba/F3 EPOR JAK2 WT
cells were serum starved overnight prior to inhibitor exposure and incubated
with 2 U/ml EPO and inhibitor for 4 hr. Total protein was normalized by Bio-
Rad Bradford quantitation, separated on 4%–12% Bis-Tris gels (Invitrogen)
and blots probed for pJAK2, JAK2, pSTAT3, STAT3, pSTAT5, Actin (CST),
and STAT5 (Santa Cruz). NIH Image J was used for densitometry. JAK hetero-
dimer formation was assessed by immunoprecipitation for JAK1 and TYK2
(BD) followed by detection of pJAK2, pJAK1, JAK2 (CST), and JAK1 and
TYK2 (BD). JAK2 phosphorylation was assessed at Y1007/Y1008 (CST),
Y221 (CST), Y570 (Millipore), and S523 (antibody generously provided by O.
Silvennoinen). For analysis of in vivo signaling, mice were sacrificed 2 hr after
oral CHZ868. Red cell lysed splenocyte single cell suspensions were pro-
cessed as described above.
Signaling Analysis in Patient Samples
The institutional review board of Memorial Sloan Kettering Cancer Center
approved sample collection and experiments. Informed consent was obtained
from all patients providing material for studies. Peripheral blood mononuclear
cells were freshly extracted using Ficoll separation and treated ex vivo with
increasing concentrations of CHZ868 or DMSO for 16 hr; 50–60 mg protein
of whole cell lysate was separated on 4%–12% Bis-Tris electrophoresis
gels, and blots were probed for pSTAT3, STAT3, pSTAT5, and actin (CST)
and STAT5 (Santa Cruz).
Animal Models of PV and MF
For treatment studies in the conditional Jak2V617F knock-in model of PV,
bone marrow from primary CD45.2 Jak2V617F mice (Mullally et al., 2010)
was mixed 1:1 with CD45.1 C57BL/6 marrow and transplanted into lethally
irradiated CD45.1 C57BL/6 recipients. Mice were randomized to the three
groups: vehicle and 30 or 40 mg/kg CHZ868 qd according to blood counts;
they were treated by oral gavage for 2–3 weeks. For studies in theMPLW515L
model of MF, CD117-enriched (Miltenyi) Balb/c marrow was transduced
with retroviral supernatant containing MSCV-hMPLW515L-IRES-GFP and in-
jected into lethally irradiated Balb/c recipients (Koppikar et al., 2010). Mice
were randomized according to blood counts to receive vehicle and 30 or
40 mg/kg CHZ868 qd for 10 days to 3 weeks. MPLW515L transplants in
C57BL/6 mice were performed analogously. For pharmacodynamic analyses,
MPLW515L Balb/c or primary Jak2V617F C57BL/6 mice received one to three
doses of CHZ868 and were sacrificed 2 hr later. For histopathology, tissues
were fixed in 4% paraformaldehyde, paraffinembedded, and stained with
H&E. For assessment of reticulin fibrosis, the silver impregnation kit for retic-
ular fibers (Bio-Optica) was used, and reticulin fibrosis was graded according
to histology scores. Animal care was in strict compliance with institutional
guidelines established by Memorial Sloan Kettering Cancer Center, the Guide
for Care and Use of Laboratory animals, and the Association for Assessment
and Accreditation of Laboratory Animal Care International. All animal proce-
dures were conducted in accordance with the Guidelines for the Care and
Use of Laboratory Animals and were approved by the Institutional Animal
Care and Use Committees at Memorial Sloan Kettering Cancer Center. For an-
alyses in the Jak2V617F BMT model, experiments were performed in strict
adherence to Swiss laws for animal welfare and were approved by the Swiss
Cantonal Veterinary Office of Basel-Stadt.
Flow Cytometry for Erythroid Progenitor Populations and Mutant
Allele Burden
In Jak2V617F andMPLW515L BMT models, allele burden was determined as
percentage of GFP+ cells in peripheral blood. In competitive transplants of
Jak2V617F knock-in marrow, allele burden was assessed as a fraction of
CD45.2 marrow or spleen cells. For analysis of the erythroid progenitor popu-
lations, marrow and spleen cells were stained for lineage markers, Sca-1,
c-Kit, CD41, CD150, CD48, CD16/32 and CD105, CD71, and Ter119 (eBio-
science) as described (Pronk et al., 2007) and analyzed on LSRFortessa or
FACSAria III (BD).
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